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S U M M A R Y
Background: Patients with neutropenic fever after 4–7 days of broad-spectrum antibiotics are given
antifungals empirically. This strategy may lead to over-treatment.
Methods: Patients with hematological malignancies undergoing intensive chemotherapy or hemato-
poietic stem cell transplantation were randomized to two arms. Patients in the ‘preemptive’ arm had
regular galactomannan (GM) assays, and received caspofungin, amphotericin or voriconazole (CAV) for
persistent febrile neutropenia if they had two positive GM results, or a positive GM result and a
computed tomography (CT) of the thorax suggestive of invasive pulmonary aspergillosis (IPA). Patients
in the ‘empirical’ arm received CAV in accordance with established guidelines.
Results: Of 27 episodes in the preemptive arm, two cases of IPA were picked up by monitoring. In six
episodes, CAV was started despite persistently negative GM readings. One additional patient received
CAV for a false-positive GM. Of 25 episodes in the empirical arm, CAV was started empirically in 10, one
of whom had CT features of IPA. By intent-to-treat and evaluable-episode analyses, respectively, the
preemptive approach saved 11% and 14% of patients from empirical antifungals. Twelve-week survival
was 85.2% in the preemptive arm and 84% in the empirical arm.
Conclusions: A preemptive approach may reduce empirical antifungal use without compromising
survival in persistently febrile neutropenic patients.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Invasive mold infections (IMIs) cause morbidity and mortality
in patients rendered neutropenic by chemotherapy.1 The risk of an
IMI rises with the depth and duration of neutropenia.2 Diagnosing
an IMI is difﬁcult, so the use of empirical antifungals for persistent
fever in neutropenia has become the standard of care.2,3 This is
supported by two pivotal studies demonstrating the beneﬁts of
empirical amphotericin deoxycholate (AmB) in neutropenic
patients who remain febrile after several days of broad-spectrum
antibiotics.4,5 These two studies form the basis of current
international recommendations on the management of febrile
neutropenia.3§ Presented at the 15th Symposium on Infections in the Immunocompromised
Host, Thessaloniki, Greece, June 22–25, 2008.
* Corresponding author. Tel.: +65 6321 3479; fax: +65 6227 5247.
E-mail address: tan.ban.hock@sgh.com.sg (B.H. Tan).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.01.011Despite their lasting inﬂuence on practice, the two pivotal
studies, however, were ‘‘underpowered, used antifungal prophy-
laxis of dubious value, and did not prove their primary hypothesis’’,
6 views echoed by other authorities.7 The empirical use of
antifungals may lead to over-treatment.8–10 Doubt has been cast
on the efﬁcacy of empirical antifungals in febrile neutropenia,
enough to ‘‘justify the demand’’ for an alternative approach using
new laboratory techniques.10
A new strategy, variously named ‘preemptive’ and ‘presump-
tive’ antifungal therapy, has emerged as an alternative to empirical
antifungals in the management of persistent fever in neutropenia.
In this strategy, antifungals are initiated only upon identiﬁcation of
a laboratory marker of fungal infection, perhaps in combination
with radiological signs. This strategy is modeled on the popular
preemptive strategy against cytomegalovirus infection in solid-
organ and hematopoietic stem cell transplantation (HSCT).11 Such
a strategy is dependent on improved diagnostics, a situation now
upon us with the advent of the galactomannan (GM) and beta-D-
glucan (BDG) assays.12,13 This situation is akin to the developmentses. Published by Elsevier Ltd. All rights reserved.
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assays in the 1990s.
We have also not been completely satisﬁed with our
prophylactic regimen, as we still see a rather high rate of
breakthrough IMI (unpublished observations), and a high rate of
use of the broad-spectrum antifungal agents. With these in mind,
we hypothesized that serial screening of GM in patients with
hematological malignancies at risk of invasive aspergillosis (IA)
and receiving effective anti-candidal prophylaxis, would obviate
the need for empirical broad-spectrum antifungal therapy.
2. Design and methods
2.1. Objectives
The primary aim of the study was to determine if serial GM
monitoring, on a background of effective anti-candidal prophylax-
is, obviated the need for empirical broad-spectrum antifungal
treatment in high-risk patients with hematological diseases and
HSCT recipients. The primary end-point was the use of a broad-
spectrum antifungal agent, either caspofungin (CAS), amphotericin
B (AmB), liposomal amphotericin (LAmB) or voriconazole (VCZ).
2.2. Study population and design
This prospective, randomized, non-blinded study was under-
taken from 14 June 2006 to 15 October 2007 in the Department
of Haematology, Singapore General Hospital, a 1600-bed tertiary
institution. Patients could be included if they met any of the
inclusion criteria and had none of the exclusion criteria (Table
1). All patients undergoing intensive chemotherapy received
oral ciproﬂoxacin 500 mg twice daily. All patients also received
oral itraconazole (ITC) (syrup formulation 200 mg three times a
day for a week, followed by capsule formulation 200 mg twice
daily until the absolute neutrophil count (ANC) rose above
0.5  109 cells/l).
While in hospital, patients were examined daily. Fever led to a
repeat physical examination, as well as a chest radiograph (CXR),
and multiple sets of blood cultures. Sputum cultures, urine
cultures, and a stool test for Clostridium difﬁcile cytotoxin could
be ordered at the physician’s discretion. Broad-spectrum anti-
biotics were started in accordance with international and
departmental guidelines.3,14Table 1
Study inclusion and exclusion criteria
Inclusion criteria
Patients were eligible if they were at least 12years of age or older, with a Karnofsk
(1) Newly diagnosed or relapsed acute leukemia or high-risk MDS receiving induct
(ANC <0.5109/l) of at least 10 days
(2) SAA receiving chemotherapy or immunosuppressive therapy using antithymocy
(3) Receiving allogeneic/autologous HSCT using myeloablative conditioning regime
(4) Consolidation regimens HyperCVAD type B or HIDAC with expected duration o
Exclusion criteria
(1) Patients who were HIV-infected
(2) Patients with uncontrolled bacteremia or active pulmonary infection at the tim
(3) Patients with pre-existing proven and probable invasive fungal infections, acco
Ascioglu et al., 200215)
(4) Patients receiving concomitant piperacillin/tazobactam or amoxicillin–clavulan
(5) Patients on palliative chemotherapy
(6) Patients with history of allergy to triazoles
(7) Patients with prior history of anaphylactic reaction to AmB
(8) Patients with serum levels of AST, ALT, ALP, or bilirubin more than 5 times the
<30ml/min
(9) Patients with expected life-expectancy <72h
MDS, myelodysplastic syndrome; ANC, absolute neutrophil count; SAA, severe aplasti
aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.Patients fulﬁlling the inclusion criteria and giving informed
consent were randomized by block randomization of 4.The
randomization list was generated by the statistician. The study
coordinator enrolled the patients according to this list. Those
randomized to the preemptive arm underwent serial GM
monitoring twice a week. The study coordinator informed the
primary hematology team of the patient’s inclusion in the study
and the arm into which the patient was randomized, and
documented this in the case records. A positive GM index (GMI),
available the next day, triggered an immediate repeat, as well as an
urgent computed tomography (CT) scan of the thorax. A second
consecutive positive GMI, or a single positive GMI plus a highly
suggestive CT thorax15 would lead to the commencement of CAS,
AmB, LAmB, or VCZ. Otherwise, GMmonitoringwas continued. The
control arm (henceforth called the ‘empirical’ arm) was provided
with the standard of care in accordance with international and
departmental guidelines.3,14 Details of the study program are
shown in Figure 1.
The hematologists managed their patients in the usual manner.
They were free to commence antifungal therapy even if the patient
had persistently negative GM readings, though educational efforts
were made throughout the study period to encourage compliance
with the study protocol. When physicians insisted on starting
caspofungin, amphotericin or voriconazole (CAV), the study end-
point was considered to have been reached, and GM monitoring
stopped. However, if an IMI was not ‘probable’ or ‘proven’ by study
criteria, the patient was eligible for randomization again in the
next cycle of chemotherapy. An infectious diseases (ID) consult
could be requested in the usual manner, and the patient would be
seen by the ID physician on-call. Managing hematologists could
also order CT scans as they saw ﬁt, regardless of the GMI. All scans
were read real-time by radiologists on duty at the time the scans
were performed. However, for data analysis and manuscript
preparation, all CT scanswere reviewed by two of the investigators,
BHT and FKC.
2.3. Ethical considerations
The study protocol was approved by the hospital’s institutional
review board and funded by the local National Medical Research
Council (NMRC; grant 0984/2005).
The study was terminated when the GM assay became a
routine service offering from themicrobiology laboratories of our
own hospital. Clinicians began to order it frequently. They score 70%, and if they had any of the following conditions:
ion or salvage chemotherapy with expected duration of neutropenia
te globulin
ns
f neutropenia (ANC <0.5109/l) of at least 10 days
e of randomization
rding to standardized deﬁnitions (see Case deﬁnitions and classiﬁcation,
ate
upper limit of normal or renal impairment with calculated creatinine clearance
c anemia; HSCT, hematopoietic stem cell transplant; AmB, amphotericin B; AST,
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Febrile Neutropenia at Risk 
Preemptive arm 
GM test twice a week 
Single GM+ 
(≥0.5)
GM−
Urgent CT 
thorax  
1) ‡CT+ 
2) Rpt GM+
Continue twice-a-week GM
Start antifungal therapy only if: 
1) Positive histopathology or 
culture from any sterile site; or  
2) Radiological studies suggestive 
of IFI 
If GM+
Empirical arm 
No GM testing 
Febrile neutropenia protocol: 
i.e., allow empirical antifungal 
therapy if indicated 
Randomization
Repeat GM  
1) ‡CT+ 
2) Rpt GM−
1) ‡CT−
2) Rpt GM+
1) ‡CT−
2) Rpt GM−
Start
antifungals* 
Start conventional AmB 
Figure 1. Studyﬂowchart (GM,galactomannan; IFI, invasive fungal infections;CT, computed tomography; zCT+denotesCTﬁndings suggestiveof invasivepulmonaryaspergillosis;
zCT denotes CT ﬁndings not suggestive of invasive pulmonary aspergillosis; *drug choices include voriconazole, caspofungin, and lipid formulations of amphotericin).
145 episodes 
screened 
69 episodes 
randomized
76 excluded:
46 refused, 30 did not 
fulfill inclusion criteria
52 episodes analyzed 
1 opted out 
16 episodes excluded 
as neutropenia <7days
Figure 2. Flow diagram depicting passage of participants through study.
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preemptive from those in the empirical arm, and hence
terminated the study.
2.4. Antigen detection
The GM assay was performed using the Platelia Aspergillus EIA
(BioRad, France), a one-stage immunoenzymatic sandwich micro-
plate assay that detects GM in human serum. The assay uses the rat
monoclonal antibodies EBA-2, directed against Aspergillus GM.
The monoclonal antibodies are used to coat the wells of the
microplates for capturing the antigen and for detection of the
antigen bound to the sensitized microplate.
Serum samples were heat-treated in the presence of ethyle-
nediaminetetraacetic acid (EDTA) in order to dissociate immune
complexes and to precipitate serum proteins that could possibly
interfere with the test. The treated serum samples and conjugate
were added to the wells coated with monoclonal antibodies and
incubated. A monoclonal antibody–GM–monoclonal antibody/
peroxidase complex is formed in the presence of GM antigen. The
strips were washed to remove any unbound material. Next, the
substrate solution was added. This reacts with the complexes
bound to the well to form a blue color reaction, if the complexes
are bound. The enzyme reaction was stopped by the addition of
acid (with color change from blue to yellow). The absorbance of
samples and controls was determined with a spectrophotometer
set at 450 and 620 nm wavelength.To exclude false-positives due to contamination in the testing
process, only sterilized consumables were used. Samples testing
positive were retested from the original specimen tube as well, to
conﬁrm a positive result.
[(Figure_2)TD$FIG]
Table 2
Characteristics of treatment episodes
Preemptive
arm
Empirical
arm
p-Value
No. of episodes 27 25
Age (years) 0.84
Mean 41.41 42.24
Median 44 45
Range 17–67 16–77
Sex 0.73
Male 16 16
Female 11 9
Underlying disorder 0.58
AML 11 14
ALL 5 6
MDS 1 0
SAA 1 0
Allo-HSCT 5 2
Auto-HSCT 4 3
Duration neutropenia(days) 0.07
Mean 18 13
Median 16 10
Range 7–41 7–31
Median duration
antifungal prophylaxis (days)
19 19 0.63
Broad-spectrum antifungal used 9 11 0.17
Voriconazole 1 1
Caspofungin 3 0
Amphotericin B 5 10
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS,
myelodysplastic syndrome; SAA, severe aplastic anemia; Allo-HSCT, allogeneic
hematopoietic stem cell transplant; Auto-HSCT, autologous hematopoietic stem
cell transplant.
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2.5. Case deﬁnition and classiﬁcation
Treatment episodes were classiﬁed as proven IA, probable IA or
possible IA, based on the deﬁnitions of the Invasive Fungal
Infections Cooperative Group of the European Organization for
Research and Treatment of Cancer/Mycoses Study Group (EORTC-
IFIG/MSG).15
‘Broad-spectrum antifungal agent’ in this article refers to CAS or
AmB or LAmB or VCZ. The use of any of these agents is abbreviated
as the use of CAV.
2.6. Statistical analysis
Patients with probable or proven IA were not eligible for
subsequent inclusion; otherwise patients could be included more
than once. Hence analysis was performed according to treatment
episodes.
Because the duration of neutropenia did not always turn out as
anticipated, treatment episodes were eventually included for
analyses only if there had been neutropenia of at least 7 days’
duration.
In the intent-to-treat (ITT) analysis, all episodes that endedwith
CAV were included, regardless of the reason for CAV. In the
evaluable-episode (EE) analysis, patients who were put on CAV
because they had probable/proven IA, or a positive GM not
amounting to proven/probable IA, were excluded.
Fisher’s exact or Chi-square tests were used for categorical
variables. The Student’s t-test was used for comparison of
continuous variables. A p-value of 0.05 was considered signiﬁ-
cant. Survival analysis was done by the method of Kaplan–Meier.
All statistical analyses were performed using SPSS software
(version 13 for Windows; IBM–SPSS, Chicago, IL, USA).
This study was registered at Clinicaltrials.gov NCT00361517.
3. Results
One hundred and twenty-ﬁve patients, representing 145
potentially eligible episodes, were screened. Eventually, 47
patients, representing 52 episodes, were randomized (Figure 2).
The characteristics of the treatment episodes are shown in
Table 2.Table 3
Proven/probable invasive mold infections picked up by galactomannan monitoring
Case, age (years) Underlying disease Type of chemotherapy
P5E2, 44 CML Allogeneic HSCT
P13E1, 36 ALL Induction
GMI, galactomannan index; CML, chronic myelogenous leukemia; ALL, acute lymphoblas
Table 4
False-positive galactomannan readings—details
Case GM index Repeat index CT thorax CA
1a P4E1 1.2 0.2 Normal No
1b P4E1 1.2 None Normal CA
2 P5E1 0.7 0.5 Normal No
3 P6E1 0.5 0.2 No signiﬁcant abnormality No
4a P1E2 1.3 0.1 Normal No
4b P1E2 0.6 0.8 Not done No
5 P8E1 0.5 0.2 Consolidation in RUL No
6 P9E1 0.6 0.2 Atelectasis No
GM, galactomannan; CT, computed tomography; CAV, caspofungin, amphotericin or voOf the 27 episodes in the preemptive arm, the primary end-
point was reached in nine (33.3%). Two were diagnosed as proven/
probable cases as a result of a positive GM result triggering further
evaluation (Table 3). One other patient received CAS for what was
eventually classiﬁed as a false-positive GM (P4E1, Table 4). There
were seven instances of false-positive GM readings in the
preemptive arm (Table 4). Of these, only one received CAV
(P4E1, Table 4). Of the remaining 24 episodes in this arm, CAV was
started empirically in six, despite persistently negative GM
readings. The details of these six patients are shown in Table 5.
One patient in the preemptive arm (P1E3) received an antifungal
late in his third enrolment despite negative GM results. At this
point he had skin nodules. However, of note he had had positive
GM readings in his previous episodes, but his physician was notGMI/day of neutropenia Mode of diagnosis
1.3/day 46 post-HSCT Probable, CT ﬁndings
1.4/day 16 Proven, CT and histopathology
tic leukemia; HSCT, hematopoietic stem cell transplant; CT, computed tomography.
V used? Alternative diagnosis Outcome
Escherichia coli bacteremia Alive
S Stenotrophomonas maltophilia bacteremia Alive
False-positive (see text) Alive
False-positive Alive
False-positive (see case reports) Alive
False-positive (see case reports) Alive
Pseudomonas aeruginosa bacteremia and pneumonia Alive
False-positive Alive
riconazole; CAS, caspofungin; RUL, right upper lobe.
Table 5
Patients started on CAV in the preemptive arm despite a persistently negative galactomannan index (GMI)
Episode Underlying
illness/chemotherapy
Neutropenic
fever prior
to CAV (days)
Duration
of CAV (days)
Alternative diagnosis CT thorax ﬁnding Outcome
P1E3 ALL/salvage 8 32 Classiﬁed as failure of monitoring Ground-glass changes
(see case reports, failure)
Alive (eventually died
outside monitoring
period)
P2E2 ALL/HSCT 9 33 Possibly engraftment syndrome
(see case reports)
Pneumonitis, pericardial
effusion (see case reports)
Died outside
monitoring period
P3E1 AML/salvage 10 11 None at the point of starting CAV.
Pre-terminal blood cultures yielded
Fusarium sp (see case reports)
Multiple lung nodules, with
several areas of consolidation
Died outside
monitoring period
P10E1 AML/mobilization 6 3 Stenotrophomonas maltophilia
bacteremia
Resolving consolidation from
pneumonia in previous
episode of neutropenia
Alive
P11E1 AML/re-induction 18 20 Escherichia coli bacteremia Bilateral pleural effusions Alive
P12E1 AML 4 1 Communication error. AmB
started, then stopped when
lab informed ward of error
Not done Alive
CAV, caspofungin, amphotericin or voriconazole; CT, computed tomography; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplant; AML, acute
myeloid leukemia; AmB, amphotericin B.
Table 6
Risk of being started on caspofungin, amphotericin or voriconazole
Preemptive arm Empirical arm p-Value
ITT: total No. of recipients of CAV/total in arm 9a/27 Total No. of recipients
of CAV/total in arm
11/25 0.57
EE: No. of empirical recipients
of CAV/No. without proven/probable
6/24b No. of empirical recipients
of CAV/No. without proven/probable
9/23c 0.36
No. of appropriate recipients of CAV according to monitoring protocol 3/27 No. of recipients of deﬁnitive
antifungal treatment
2/25 1.00
ITT, intent-to-treat analysis; EE, evaluable-episode analysis; CAV, caspofungin, amphotericin or voriconazole.
a Includes one who received it because of a false-positive galactomannan assay (see Table 5).
b See Table 4 for details.
c Of the two patients with proven/probable invasive fungal infection, one received AmB empirically (see text) and the other received it because of a clinical sign (see
Supplementary Material).
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1 in the Supplementary Material). Hence, in the ITT analysis, the
risk of being started on CAV in the preemptive arm was 33.3% (9/
27). In the EE analysis, the risk of being started on CAV for patients
randomized to the preemptive arm was 25% (6/24).
Of 25 episodes in the empirical arm, 10 patients (40%) were
started empirically on CAV, and one patient was started on AmB
because of paronychia of the thumb (which turned out to be caused
by Fusarium sp). One of the 10 patients started empirically on CAV
also had a CT thorax with features characteristic of invasive
pulmonary aspergillosis (IPA); she also was found to have an
elevated GMI, done after recovery of ANC at the discretion of her
physician (see Supplementary Material). The other nine patients
put empirically on CAV did not have either proven or probable
invasive fungal infection (IFI). The risk of being started on CAVwas
44% (11/25) by ITT analysis and 39.1% (9/23) by EE analysis, for
patients randomized to the empirical arm.
Hence the risk of being put empirically on CAVwas greater in the
empirical than in thepreemptive arm, though thedifferencewasnot
statistically signiﬁcant (Table 6). In the ITT analysis, the preemptive
approach saved about 11% of patients from empirical antifungals,
while in the EE analysis the preemptive approach saved 14% of
patients from empirical antifungals, without adverse consequences.
Twelve-week survival was 85.2% in the preemptive arm and
84% in the empirical arm.
4. Discussion
In this study, we demonstrated that holding back antifungals in
the persistently febrile neutropenic patient until the GMI waspositive was a potentially viable strategy. Such an approach,
variously termed ‘preemptive’ and ‘presumptive’, represents an
alternative to empirical antifungals.16–18 It is modeled on the
successful strategy against CMV in transplantation.19
We employed prophylaxis in this study as it is the routine in our
department for patients likely to experience prolonged neutrope-
nia. The use of antifungal prophylaxis in febrile neutropenia is
supported by international guidelines.20 We used ITC because of
evidence for its efﬁcacy in this setting, as well as a relatively high
rate of IA in our institution.21,22 Though ITC is ‘mold-active’, our
experience, along with that in the literature, suggests that the
prophylactic efﬁcacy of ITC in preventing IA is patchy.23
Glasmacher et al. compared ﬂuconazole against ITC as prophylaxis
in neutropenic patients and found that the rates of breakthrough IA
were similar in the two arms.23
Oshima et al. reviewed their experience with a ‘presumptive’
strategy in which an antifungal was started only when a GMI or a
BDG assay was positive, or when a CT thorax showed nodules.18
They concluded that the presumptive strategy was safe—the only
death was attributed to progression of acute myeloid leukemia.18
Because of the retrospective nature of this study, a bias cannot be
excluded.16
The use of diagnostic modalities to trigger antifungals has been
shown to reduce the need for their use. In a non-randomized study,
Maertens et al. assayed GM daily in at-risk hematological patients,
until neutropenia resolved.9 They also performed CT thorax and
bronchoscopy in those at high risk for an IFI. Whereas 35% of the
patients would have been started on broad-spectrum antifungals
had the investigators adopted the traditional empirical approach,
only 7.7% of the patients in this cohort eventually received LAmB.
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one of zygomycosis was.9
Cordonnier et al. compared the empirical approach with a
preemptive approach.17 Patients with hematological malignancies
(after chemotherapy or an autologousHSCT)whowere febrile after
4 days of broad-spectrum antibiotics were started on antifungals if
theywere randomized to the empirical treatment arm. If theywere
randomized to the preemptive arm, they would only be started on
an antifungal if they developed one of several triggers, such as
imaging-documented pneumonia or a positive GM test. GM
screening was performed twice a week. Forty-two percent of
patients in the empirical arm and 48% of those in the preemptive
arm received prophylaxis. Two-week survival was 97% in the
empirical arm and 95% in the preemptive arm (p = 0.31). The
incidence of IFI was signiﬁcantly higher in the preemptive than in
the empirical arm; these included candidiasis in the preemptive
arm. (All patients with candidiasis did not receive azole
prophylaxis.) The preemptive arm enjoyed statistically signiﬁcant
cost-savings.17
Our study also compared the two different approaches to
antifungal therapy in febrile neutropenic patients in a randomized
manner. It was different from that of Cordonnier et al. because the
trigger for antifungal therapy in the preemptive arm was the
positive GM assay ( a positive CT thorax), and because all patients
were on Candida-active prophylaxis. Like the study of Cordonnier et
al., our results suggest that the preemptive approach may reduce the
use of broad-spectrum antifungals without compromising survival.
One shortcoming of our approach is that the GM assay per se is
inadequate as the trigger in a preemptive strategy. The CMV pp65
antigenemia assay and the CMV PCR are sensitive and speciﬁc
enough for a preemptive approach to CMV prevention. Even then
‘missed’ cases leading physicians to commence anti-CMV agents
for treatment purposes are well reported.24,25 The GM assay will
not pick up fusariosis, scedosporiosis, or zygomycosis. The cases of
fusariosis seen in this small study suggest that, rare though they
are, these are truly emerging pathogens. The GM assay therefore is
not failsafe for use as the only trigger for antifungals in a severely
immunocompromised and highly vulnerable population.
Apart from its inability to pick up these rarer molds, the GM
assay has a rather poor sensitivity—Pfeiffer et al. found the
sensitivity to be 71% in a meta-analysis.26 This ﬁgure falls in
patients on mold-active prophylaxis.27 The negative predictive
value (a little over 80%) is inadequate for sole use in such a
strategy.28,29 On the other hand, as may be seen from the
Supplementary Material, failure to take positive GM results
seriously (after ruling out obvious causes of false-positivity)
may lead to the diagnosis of IA being missed.
The relative freedom given to managing physicians may be
regarded as a ﬂaw. However, it was crucial in allowing the study to
be carried out, as at that time no data from a randomized clinical
trial existed to support its use. The freedom they were given,
however, was used to see how effective the study strategy was in
comparison with the more established empirical approach. This
strategy of giving ﬂexibility to attending physicians in their
compliance with study algorithms has been used before.30 In a
study conceptually similar to ours, a biomarker (procalcitonin)was
used to guide the cessation of antibiotics. Primary physicians were
allowed to continue antibiotics even when the algorithm advised
stopping.30
As it was, by evaluable-episode analysis, the proportion of
patients in the preemptive armwho received CAVwas numerically
two-thirds that of patients in the empirical arm, though the
difference was not statistically signiﬁcant. Had the GM assay a
better negative predictive value for IA, the attending clinicians
might have been less nervous. Segal et al. pointed out that the
better the diagnostic tool was at detecting an occult fungalinfection early, themore likely physicians would be to ‘‘not modify
the antifungal regimen for patients with negative screening
results’’.7 It is possible that our small sample size may have
prevented a true difference to be seen.
Nevertheless the results are heartening. Although we random-
ized study subjects, the patients in the preemptive arm had mean
and median periods of neutropenia that were marginally longer
than those in the empirical arm (p = 0.07). Despite this disadvan-
tage, the preemptive arm did not suffer an increasedmortality. The
withholding of empirical antifungals may have been balanced by
the appropriate initiation of antifungals in two patients whose IPA
was picked up by regular GM monitoring.
Unfortunately, we had to terminate the study early. Could we
have stopped physicians looking after patients in the empirical arm
from ordering GM tests when they became easily available? On
ethical grounds alone, we felt that we could not. This was based on
the premise that ‘‘research is ethically justiﬁable only if it is..
morally acceptable within the communities within which it is
carried out’’.31 At the time of our study, no guideline recommended
routine regular GM screening in febrile neutropenic patients. Given
the high mortality of IA, it was understandable that physicians
would want every available tool to diagnose IA early. In 2008, a
publication recommended daily GM monitoring in neutropenic
patients with persistent fever despite broad-spectrum antibacter-
ials.32
In conclusion, this prospective, randomized study showed that,
in the setting of effective anti-candidal prophylaxis, CAV may be
held off safely in the majority of febrile neutropenic patients, if the
GMI is persistently negative. Our study suggests the safety of a
preemptive approach to antifungal therapy in persistently febrile
neutropenic patients.
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